ASXL1突变、既往血管并发症与诊断年龄可预测85例WHO定义真性红细胞增多症患者生存
该研究在85例WHO定义的真性红细胞增多症(PV)患者中,采用髓系测序panel检测JAK2 V617F以外的附加突变,发现78%患者至少存在一种附加突变,以表观遗传修饰基因(TET2、DNMT3A、ASXL1)突变最常见。ASXL1突变与总生存期较差显著相关,将其与诊断年龄及诊断前血管并发症联合可划分三个预测生存的风险组。
要点
- 78%的PV患者存在JAK2 V617F以外的附加突变,表观遗传修饰基因突变最常见。
- ASXL1突变与PV患者总生存期较差显著相关。
- 联合ASXL1突变、诊断年龄及诊断前血管并发症可划分三个生存风险组。
核心结论
- ASXL1突变与PV患者总生存期较差显著相关。
- 联合ASXL1突变、诊断年龄及诊断前血管并发症可定义三个预测生存的风险组。
研究设计与样本
- 研究纳入85例WHO定义的真性红细胞增多症(PV)患者,评估临床数据与血液值。
- 采用髓系测序panel筛查JAK2 V617F及JAK2外显子12突变以外的附加突变。
主要发现
- 78%的PV患者检测到至少一种JAK2 V617F以外的附加突变。
- 表观遗传修饰基因(如TET2、DNMT3A、ASXL1)的附加突变最为常见。
- ASXL1突变与总生存期较差显著相关。
关键数值与推荐
- 附加突变最常见于表观遗传修饰基因,包括TET2、DNMT3A和ASXL1。
- 基于ASXL1突变、诊断年龄及诊断前血管并发症划分三个风险组以预测生存。
临床怎么用
- 对PV患者可考虑检测ASXL1突变,并结合诊断年龄及诊断前血管并发症进行生存风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Polycythaemia vera (PV) patients have an overall comparatively favourable prognosis, but disease progression is very heterogeneous and life-threatening thrombosis and bleedings are frequent complications in untreated disease. Moreover, transformation to more severe secondary myelofibrosis and acute myeloid leukaemia can occur. The aim of this study was to identify gene mutations that could be used together with clinical data as prognostic markers to guide treatment decisions in PV patients. A well-characterized WHO-defined cohort of PV patients was used. Clinical data and blood values were evaluated and a myeloid sequencing panel was used to screen for additional mutations other than the diagnostic JAK2 V617F and JAK2 exon 12 mutations. In 78% of the PV patients, at least one mutation additional to JAK2 V617F was detected. Additional mutations in genes coding for epigenetic modifiers, like TET2, DNMT3A and ASXL1, were most frequent. When correlated to overall survival, mutations in ASXL1 were significantly associated with inferior survival. In an attempt to obtain prognostic guidance in a larger number of patients, the presence of ASXL1 mutations was combined with age and vascular complications prior to diagnosis. Based on these data we were able to define three risk groups that predicted survival.
引用
- Andréasson B, Pettersson H, Wasslavik C, et al. ASXL1 mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO-defined polycythaemia vera patients. Br J Haematol. 2020. PMID: 32066200. doi:10.1111/bjh.16450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。